SOME GOOD NEWS! After the halting of Oxford’s COVID-19 vaccine due to an unexplained illness, a probable adverse reaction on one of the participants in trials, we finally have some ray of hope while we sit out the pandemic. Johnson & Johnson’s Coronavirus vaccine candidate for JNJ-78436735 known as Ad26.COV2.S, has entered the final phase 3 of clinical trials which will be administered on 60, 000 volunteers. According to New York Magazine’s Intelligencer, the company has kicked off study about the vaccine on the large sample group on people from Coronavirus hotspots like U.S., South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru.
Now, while it is not something other competitors haven’t done already but one is hopeful because, if successful, it will be the only single-shot vaccine in the market. Not to mention, it doesn’t need to be stored in sub-zero temperatures. Reportedly, it can remain stable for two years at -20 °C and at least three months at 2-8° C. This makes the vaccine candidate compatible with standard vaccine distribution channels and would not require new infrastructure to get it to the people who need it.
Alex Gorsky, Chairman and CEO, Johnson & Johnson, in a statement said, “As COVID-19 continues to impact the daily lives of people around the world, our goal remains the same – leveraging the global reach and scientific innovation of our company to help bring an end to this pandemic. As the world’s largest healthcare company, we are bringing to bear our best scientific minds, and rigorous standards of safety, in collaboration with regulators, to accelerate the fight against this pandemic.”
“This pivotal milestone demonstrates our focused efforts toward a COVID-19 vaccine that are built on collaboration and deep commitment to a robust scientific process. We are committed to clinical trial transparency and to sharing information related to our study, including details of our study protocol.”
Apart from its advantages over rival companies, there is another thing has somehow managed to salvage the plummeting belief of many in COVID-19 immunity. J&J is expecting results soon and it will be able to tell more about the vaccine’s effectiveness by the end of 2020. However, it is imperative to note that the vaccine in unlikely to be ready before 2021 for public consumption even amidst pressure by the Donald Trump administration.
Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson even stated, “We greatly value the collaboration and support from our scientific partners and global health authorities as our global team of experts work tirelessly on the development of the vaccine and scaling up our production capacity with a goal to deliver a vaccine for emergency use authorization in early 2021.”
Here’s to hoping anyway!
Cover Image: Shutterstock